NSABP FC-12
NSABP FC-12
A Single Arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer who are ctDNA-positive after Curative Surgery and Adjuvant Chemotherapy
Protocol Chair: Priya Rastogi, MD
Protocol Officer: Shannon Puhalla, MD
Patient Population:
Patients with Stage II/III Colon Cancer who are ctDNA-positive after Curative Surgery and Adjuvant Chemotherapy
Target Accrual: 31 patients
Status: Active, Not Recruiting
ClinicialTrials.gov Identifier: NCT05178576
A Single Arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer who are ctDNA-positive after Curative Surgery and Adjuvant Chemotherapy
Protocol Chair: Priya Rastogi, MD
Protocol Officer: Shannon Puhalla, MD
Patient Population:
Patients with Stage II/III Colon Cancer who are ctDNA-positive after Curative Surgery and Adjuvant Chemotherapy
Target Accrual: 31 patients
Status: Active, Not Recruiting
ClinicialTrials.gov Identifier: NCT05178576